The microsite is supported by AbbVie.

As a global, research-driven biopharmaceutical company, AbbVie is committed to treating serious, mostly chronic diseases. Research and innovation are the foundation of the company’s operations. Therapeutic areas include dermatology.

Highlights

Video contributions

Professional article
View Post

Is good still good enough for you and your AD patients? Raising the standard of treatment for atopic dermatitis

We are pleased to invite you to our roadshow on atopic dermatitis (AD). The roadshow will take place from February 5 to 8, 2024 with the expert Professor Jonathan Silverberg (George Washington University, Washington, DC, USA)…. This content can only be access by registered users. Log In Register
View Post

Achieving high treatment goals with the Minimal Disease Activity concept

Patients with moderate to severe atopic dermatitis suffer from the physical and psychological effects of the disease and yet do not receive adequate treatment with systemic therapies, or often only after a delay [1-3]. The Minimal Disease Activity approach aims to consistently identify patients who are candidates for advanced treatment, combining the treat-to-target concept with shared decision-making between patients and physicians [4]…. This content can only be access by registered users. Log In Register
View Post

Scores in chronic inflammatory dermatoses – are they worth the effort?

Whether scores are really necessary to determine the severity of psoriasis and atopic dermatitis is debatable. The expert PD Dr. med. Julia-Tatjana Maul and the expert Prof. Dr. med. phil. nat. Christoph Schlapbach in an Oxford-style debate moderated by Prof. Nikhil Yawalkar, MD, at the AbbVie Satellite Symposium at this year’s SGDV Congress…. This content can only be access by registered users. Log In Register
View Post

Modern therapies for atopic dermatitis and psoriasis

Atopic dermatitis and psoriasis often place a physical and psychological burden on sufferers [1, 2]. At this year’s Swiss Derma Day in Lucerne and at the virtual SSAI Allergology & Immunology Update, three experts from Inselspital Bern gave an overview of current treatments, going into more detail about the efficacy and safety of various JAK inhibitors and biologics…. This content can only be access by registered users. Log In Register
View Post

New therapeutic era for patients with atopic dermatitis and psoriasis

Atopic dermatitis and psoriasis are among the most common skin diseases and often impose a great physical, psychological and social burden on those affected [1–4]. A review of the last SGDV and EADV congresses shows that the spectrum of therapy for the two inflammatory dermatoses has greatly expanded thanks to the improved understanding of the pathophysiology…. This content can only be access by registered users. Log In Register
View Post

Biologics in head-to-head comparison [1–3]

Biologics have become popular in psoriasis management due to their improved efficacy and advantageous safety profile over conventional therapies [4]. That individual biologics with different target cytokines may differ in efficacy is demonstrated by the results of several head-to-head studies [1–3]…. This content can only be access by registered users. Log In Register
View Post

“No one needs to walk around with psoriasis these days”.

In the second part of his interview, Andreas Pinter, MD, University Hospital Frankfurt/Main, Germany, explains how IL-17 and IL-23 inhibitors differ in the treatment of psoriasis in terms of mechanism of action, clinical trial data, and applicability in practice, and how ambitious therapeutic goals can be better achieved in the future…. This content can only be access by registered users. Log In Register
View Post

“Patients want a life without psoriasis”.

In the run-up to his nationwide roadshow from October 6 to 8, 2020, Andreas Pinter, MD, University Hospital Frankfurt/Main, Germany, explained the importance of interleukin (IL)-23 inhibitors for modern psoriasis therapy and reported on his experience with this treatment option as well as on the wishes and expectations of his patients…. This content can only be access by registered users. Log In Register
View Post

“I forgot I had psoriasis.”

With currently available biologics, patients with moderate to severe plaque psoriasis can achieve rapid and durable symptom relief and a sustained improvement in quality of life [1,2]. Using a case report, Ahmad Jalili, MD, illustrates how such ambitious treatment goals became reality for a patient with severe psoriasis vulgaris…. This content can only be access by registered users. Log In Register